In summary, our findings demonstrate that XI-006 is a promising new potential therapeutic for the treatment of Ewing sarcoma as it induced potent p53-independent apoptosis at non-DNA damaging concentrations specifically in Ewing sarcoma cell lines. Here, TP53 is linked to Ewing sarcoma.